Mineralys Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was dated March 21, 2024. Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled or resistant hypertension and chronic kidney disease. It has no approved products and generated no revenue.
Business Context and Development Progress
- Target-HTN, a 200-subject Phase 2 trial, showed placebo-adjusted systolic blood-pressure reductions of 9.6 mmHg with 50 mg once daily and 7.8 mmHg with 100 mg once daily; results were statistically significant.
- Advance-HTN, a 261-subject pivotal Phase 2 trial, began in April 2023. Topline data were expected in the fourth quarter of 2024.
- Launch-HTN, a Phase 3 trial expected to enroll up to approximately 1,000 subjects, began in December 2023. Topline data were expected in the second half of 2025.
- An open-label extension trial began in mid-2023 to collect longer-term safety and efficacy data.
- Explore-CKD is a Phase 2 trial in hypertensive patients with Stage 2 to 3b CKD. The company modified the study to require SGLT2-inhibitor treatment, lowered the eGFR threshold to 30 mL/min/1.73m2, eliminated the original Part B, and shortened treatment periods to four weeks. Topline data were expected between the fourth quarter of 2024 and the first quarter of 2025.
Financial Results and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $70.4 million | $26.3 million | +$44.1 million |
| General and administrative expense | $14.3 million | $5.2 million | +$9.1 million |
| Total operating expenses | $84.7 million | $31.5 million | +$53.2 million |
| Other income, net | $12.8 million | $1.7 million | +$11.1 million |
| Net loss | $71.9 million | $29.8 million | Loss increased by $42.1 million |
| Net loss per share | $1.99 | $5.77 | Not directly comparable because of the IPO and share-count increase |
| Net cash used in operating activities | $81.2 million | $29.2 million | Cash use increased by $52.0 million |
- Cash, cash equivalents, and investments totaled $239.0 million at December 31, 2023, including $49.3 million of cash and cash equivalents and $189.7 million of U.S. Treasury investments.
- Total assets were $251.6 million and current liabilities were $10.5 million. The filing does not identify outstanding debt; the balance sheet shows no debt line item.
- Investing cash outflow was $160.5 million, primarily reflecting purchases of marketable securities after the IPO. Financing cash inflow was $203.2 million, primarily from the IPO.
- Interest income increased to $12.8 million from $1.7 million, largely because of the larger investment portfolio following the IPO.
- Management believed year-end cash, cash equivalents, and investments would fund operations for at least 12 months, but stated that substantial additional capital will be required to complete development and potential commercialization.
- In February 2024, the company raised approximately $120.0 million in gross proceeds through a private placement of common stock and pre-funded warrants. This subsequent financing was not included in year-end 2023 cash balances.
Material Changes Versus 2022
- Research and development expense rose primarily because of the pivotal clinical program, higher clinical and preclinical costs, manufacturing and regulatory activity, increased compensation, and $9.0 million of Mitsubishi development milestone payments.
- General and administrative expense increased because of public-company professional fees, higher compensation and stock-based compensation, and director and officer insurance.
- The company completed its IPO in February 2023, receiving approximately $201.4 million of net proceeds. Convertible preferred stock converted into common stock at the IPO.
- Shares outstanding increased substantially; 41.1 million common shares were outstanding at December 31, 2023, compared with 6.4 million common shares at December 31, 2022, before giving effect to later 2024 financing activity.
- The company transitioned from an earlier-stage development program to a pivotal hypertension program, including initiation of its first Phase 3 trial.
Outlook, Risks, Contingencies, and Unusual Items
- Management expects operating expenses and losses to increase substantially as clinical trials advance, regulatory and manufacturing capabilities expand, intellectual-property costs continue, and public-company expenses rise.
- Lorundrostat remains the company’s only product candidate; failure or delay in its development, regulatory approval, or commercialization would materially affect the company.
- Target-HTN safety findings included dose-dependent potassium increases, six transient potassium readings above 6.0 mmol/L, one possibly drug-related serious hyponatremia event, and reversible reductions in eGFR. Larger and longer trials may reveal additional risks.
- The company relies on third-party contract research organizations, clinical sites, and manufacturers and has no commercial manufacturing arrangements or redundant supply source.
- The Mitsubishi license requires up to $155.0 million of commercial milestone payments, up to an additional $10.0 million for a second indication, and tiered royalties ranging from the mid-single digits to 10% of net sales. Development milestones totaling $9.0 million were paid in 2023, satisfying the stated development milestone obligations.
- Termination of the Mitsubishi license could eliminate the company’s rights to develop and commercialize lorundrostat.
- The company faces competition from other aldosterone synthase inhibitor programs, alternative mechanisms, and low-cost generic antihypertensive therapies.
- The company reported no material legal proceedings and no cybersecurity incident that had materially affected, or was reasonably likely to materially affect, the business as of the filing date.
- Management concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2023. As an emerging growth company, the company’s independent auditor was not required to provide an attestation opinion on internal control effectiveness.
Important Facts for Investors to Verify
- Advance-HTN topline results, including the magnitude, statistical significance, durability, and safety of blood-pressure effects.
- Launch-HTN enrollment, execution, topline results, and the company’s ability to progress toward an NDA and potential approval.
- Explore-CKD results, particularly blood-pressure and urinary albumin-creatinine-ratio outcomes under SGLT2-inhibitor background therapy.
- Potassium, sodium, eGFR, hypotension, and other safety outcomes as the lorundrostat safety database expands.
- Cash burn and runway after the February 2024 financing, including the impact of pivotal-trial costs and potential future capital raises.
- Potential dilution from the 2024 private placement, pre-funded warrants, stock options, restricted stock awards, and employee equity plans.
- Remaining Mitsubishi milestone, royalty, license-compliance, and termination obligations.
- Clinical-trial enrollment, contract-manufacturer capacity, supply continuity, intellectual-property validity, and competitive developments.